Published On: Wed, Oct 19th, 2016

Broker Changes For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)


Recently stock market analysts have updated their consensus ratings on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Most recent broker ratings

10/05/2016 – Karyopharm Therapeutics Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 18 price target on the stock.

09/08/2016 – Karyopharm Therapeutics Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 16 price target on the stock.

09/06/2016 – Karyopharm Therapeutics Inc. had its “outperform” rating reiterated by analysts at Robert W. Baird. They now have a USD 16 price target on the stock.

08/30/2016 – Karyopharm Therapeutics Inc. was upgraded to “buy” by analysts at Jefferies. They now have a USD 12 price target on the stock.

05/27/2016 – Raymond James began new coverage on Karyopharm Therapeutics Inc. giving the company a “outperform” rating. They now have a USD 13 price target on the stock.

03/16/2016 – Karyopharm Therapeutics Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 16 price target on the stock.

03/15/2016 – Karyopharm Therapeutics Inc. was downgraded to “underperform” by analysts at Bank of America Merrill Lynch. They now have a USD 11 price target on the stock.

12/22/2015 – Karyopharm Therapeutics Inc. had its “buy” rating reiterated by analysts at FBR Capital Markets. They now have a USD 20 price target on the stock.

12/22/2015 – Canaccord Genuity began new coverage on Karyopharm Therapeutics Inc. giving the company a “buy” rating. They now have a USD 20 price target on the stock.

11/10/2015 – Karyopharm Therapeutics Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 20 price target on the stock.

08/12/2015 – Karyopharm Therapeutics Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 42 price target on the stock.

03/23/2015 – Karyopharm Therapeutics Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 58 price target on the stock.

03/17/2015 – Karyopharm Therapeutics Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 53 price target on the stock.

11/05/2014 – Barrington Research began new coverage on Karyopharm Therapeutics Inc. giving the company a “buy” rating. They now have a USD 54 price target on the stock.

03/20/2014 – Karyopharm Therapeutics Inc. had its “” rating reiterated by analysts at RBC Capital.

Karyopharm Therapeutics Inc. has a 50 day moving average of 9.41 and a 200 day moving average of 8.42. The stock’s market capitalization is 310.23M, it has a 52-week low of 4.83 and a 52-week high of 19.41.

The share price of the company (NASDAQ:KPTI) was up +1.41% during the last trading session, with a high of 8.73 and the volume of Karyopharm Therapeutics Inc. shares traded was 630730.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.